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Broadly HIV-1–neutralizing antibodies (BnAbs) display one or more unusual traits, including a long heavy
chain complementarity-determining region 3 (HCDR3), polyreactivity, and high levels of somatic mutations.
These shared characteristics suggest that BnAb development might be limited by immune tolerance controls.
It has been postulated that HIV-1–infected individuals with autoimmune disease and defective immune tolerance mechanisms may produce BnAbs more readily than those without autoimmune diseases. In this study,
we identified an HIV-1–infected individual with SLE who exhibited controlled viral load (<5,000 copies/ml) in
the absence of controlling HLA phenotypes and developed plasma HIV-1 neutralization breadth. We collected
memory B cells from this individual and isolated a BnAb, CH98, that targets the CD4 binding site (CD4bs)
of HIV-1 envelope glycoprotein 120 (gp120). CH98 bound to human antigens including dsDNA, which is specifically associated with SLE. Anti-dsDNA reactivity was also present in the patient’s plasma. CH98 had a
mutation frequency of 25% and 15% nt somatic mutations in the heavy and light chain variable domains,
respectively, a long HCDR3, and a deletion in the light chain CDR1. The occurrence of anti-dsDNA reactivity
by a HIV-1 CD4bs BnAb in an individual with SLE raises the possibility that some BnAbs and SLE-associated
autoantibodies arise from similar pools of B cells.
Introduction
Broadly HIV-1–neutralizing antibodies (BnAbs) have been
isolated that bind to multiple epitopes on the envelope glycoproteins gp120 and gp41 (reviewed in ref. 1). 2G12 recognizes
a posttranslational glycan epitope on gp120 (2, 3). CH103–
CH106 (4), b12 (5, 6), VRC01 (7), and numerous other mAbs
with VRC01-like characteristics, such as VRC03, VRC-PG04,
CH30–CH34, and the HAAD motif antibodies (7–9), recognize
the CD4 binding site (CD4bs). HJ16 binds to an epitope near the
CD4bs (10). PG9 and PG16, CH01–CH04, and PGT141–PGT145
recognize conformational epitopes in the gp120 V1/V2 region
with binding dependence on V2 asparagine residue 160 (11–13).
PGT121–PGT123, PGT135–PGT137, PGT125–PGT128,
PGT130, and PGT131 recognize a diverse set of carbohydrate or
carbohydrate-dependent epitopes in the gp120 V3 region (13).
3BC176 and 3BC315 recognize a conformational HIV-1 spike
epitope in the proximity of the V3 loop and the CD4i site that
is exposed in part by CD4 binding (14). Finally, 2F5 (2, 15, 16),
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4E10 (2, 17), 10E8 (18), and Z13 (19) bind to the membrane
proximal external region (MPER) of gp41.
Each of these antibodies displays one or more unusual characteristics, such as polyreactivity with human and/or nonhuman
antigens, long heavy chain complementarity-determining region 3
(HCDR3) loops, and high levels of somatic mutations (1, 13, 20–23).
These traits suggest that the development of these types of BnAbs
may be limited by immune tolerance controls that impede the
required tortuous or polyreactive BnAb maturation pathways (20,
21, 24). This notion is supported by a number of observations in
2F5 VH×VL knockin mice: targeted expression of the 2F5 VHDJH/
VLJL rearrangements triggered a near-complete B cell developmental blockade at the pre-B to immature B cell stage (25); even
when clonal deletion mechanisms were circumvented, 2F5 VHDJH/
VLJL-expressing broadly neutralizing B cell rescue was limited by κ
chain editing and an anergic phenotype (26); and MPER-specific
serum neutralizing IgG responses were elicited in 2F5 knockin
mice immunized with MPER-lipid complexes by rescuing the
anergic self-reactive 2F5-expressing B cells that survived the B cell
developmental blockade (26).
We have previously suggested that the paucity of subjects developing BnAbs may be due to the frequent deletion of B cell precursors that acquire autoreactivity during their maturation process
(at either early or late stages) and hypothesized that HIV-1–infected subjects with autoimmune diseases might be capable of devel-

The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 4   April 2014

1835

research article

Figure 1

Identification of neutralizing CD4bs antibodies in CH5329 serum. (A) CH5329 plasma and mAb CH98 neutralization profiles, measured as ID50 and
IC50,respectively, in TZM-bl assay. Transmitted/founder HIV-1 isolates are italicized. For plasma neutralization: red, ID50 >1,000; orange, ID50 100 to
1,000; yellow, ID50 >20 and <100; white, ID50 <20 (absence of neutralization). For CH98 BnAb: red, IC50 <1 μg/ml; orange, IC50 1 to 50 μg/ml; white,
IC50 >50 μg/ml (absence of neutralization). (B) Differential binding by CH5329 serum to the RSC3 protein and the CD4bs knockout RSC3Δ371I/
P363N, graphed as ELISA endpoint titer (final reciprocal serum dilution with background-corrected OD ≥0.1). (C) CD4bs-directed neutralizing
activity in CH5329 serum, shown as percent reduction in ID80 in the presence of RSC3 compared with the knockout RSC3Δ371I/P363N against
HIV-1 JRFL and HxB2 strains. Values for the BnAbs VRC01 and 2F5 are included as positive and negative control, respectively. In B and C, error
bars represent SEM from 2 independent experiments.

oping BnAbs in the context of their autoreactive humoral response
(24, 26–28). The observations that HIV-1 infection is reported with
a disproportionately low frequency among subjects with SLE support this hypothesis (29–34).
To date, there have been no reports of studies of the HIV-1 antibody repertoire of SLE subjects from whom BnAbs have been
isolated. Here, we describe CH98, an HIV-1 CD4bs BnAb isolated
from an HIV-1–infected individual with SLE (subject CH5329; see
Methods). CH98 displayed a number of unusual antibody traits
shared by autoimmune disease autoantibodies.
Results
CH5329 plasma neutralization and isolation of CH98. In a multiclade,
multitier panel of HIV-1 strains, consisting of 4 tier-1A, 4 tier-1B,
and 34 tier-2 isolates, including 9 transmitted/founder viruses,
plasma from subject CH5329 neutralized 41 of 42 HIV-1 strains
(97.6%), with a mean ID50 titer of 925 (range, 21–9,204; Figure 1A).
The only HIV-1 strain that was not neutralized, G.P0402, was a clade
G. CH5329 plasma was screened in 2 different but complementary
assays for CD4bs activity. CH5329 plasma bound to the HIV-1 Env
resurfaced core 3 (RSC3) protein with a mean endpoint titer 5-fold
1836

higher than that of the RSC3Δ371I/P363N protein (Figure 1B and
Supplemental Figure 1; supplemental material available online with
this article; doi:10.1172/JCI73441DS1), indicative of the presence
of CD4bs mAbs (7). The RSC3 protein preferentially blocked the
neutralization ability of CD4bs mAbs such as VRC01, but not mAbs
directed against other sites, such as the gp41-binding 2F5 BnAb.
However, the ability of RSC3 protein to block neutralizing activity
in HIV-infected sera is rare (35) and indicative of the presence of
CD4bs neutralizing antibodies (7, 8). Therefore, the 30%–55% reduction we observed in total serum neutralization against 2 different
HIV-1 strains, HxB2 and JRFL (Figure 1C), indicated that CD4bs
antibodies markedly contribute to plasma neutralization.
mAb CH98 VHDJH and VLJL gene segments were isolated from a
clonal memory B cell culture containing 29 ng/ml IgG at the end
of stimulation with culture supernatant that bound to RSC3 but
not RSC3Δ371I, and were expressed as a full recombinant IgG1
mAb (11, 36, 37). CH98 neutralized 27 of 43 HIV-1 isolates (62.8%),
with a median IC50 neutralization level of 4.2 μg/ml (range,
<0.02–49 μg/ml), accounting for 65.9% of the observed plasma
neutralization breadth (Figure 1A). No other antibodies were
retrieved that bound to RSC3 or neutralized the A.Q23.17 HIV-1
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strain, which was selected to screen culture supernatants for heterologous neutralizing activity (see Methods). Thus, the frequency
of peripheral blood circulating CD4bs neutralizing antibodies in
this subject was estimated to be 0.003%.
Characteristics of CH98. CH98 uses the VH3–30 gene segment, notably not the VH1–2 or VH1–46 segments commonly associated with
VRC01-like CD4bs BnAbs (8, 9), paired with the Vλ2–23 light chain
gene segment. CH98 is highly mutated, with VHDJH and VLJL mutation frequencies of 25.3% and 15.8%, respectively, and displays a long
HCDR3 of 21 aa (Supplemental Table 1). From 454 pyrosequencing, we identified 4 additional VHDJH rearrangements in the CH98
clonal lineage, and all were highly mutated and shared numerous
mutations with the CH98 VHDJH (Supplemental Figures 2 and 3).
The CH98 light chain CDR 1 (LCDR1) is 27 nt long and underwent a 15-nt deletion preceded by an activation-induced cytidine
deaminase (AID) hotspot (AGT; Supplemental Figure 4). TGT motifs
are also present near the start and the end of this deletion (Supplemental Figure 4), raising the hypothesis that slipped-strand synthesis
may have occurred at this position. It is also worth noting that the
CH98 VL/JL gene segment rearrangement had a very long n-region
insertion of 24 nt in the LCDR3 that were not encoded by either of
the VL2–23 or JL3 germline sequences (Supplemental Figure 4).
CH98 epitope mapping. CH98 bound to RSC3 protein (IC50,
0.51 μg/ml), but not to RSC3Δ371I/P363N; in contrast to the
CD4bs BnAb VRC01, CH98 did not bind to RSC3 G367R mutant
or to the gp120 outer domain stabilized protein OD4.0 (Supplemental Table 2). Binding to WT YU2 gp120 Env (IC50, 0.03 μg/ml)
was abrogated by the D368R mutation, which disrupts a key contact residue within the CD4bs, but not by the I420R mutation
(IC50, 0.11 μg/ml), which disrupts the CCR5 coreceptor binding
site (Supplemental Table 2). Also, CH98 potently neutralized the
HIV-1 YU2 strain (IC50, 0.9 μg/ml). Therefore, we epitope mapped
CH98 on a panel of YU2 gp120 core protein mutants previously
used to map other mAbs binding within and outside the CD4bs
(38, 39). We compared the binding profile of CD4bs BnAb CH98
with those of other CD4bs BnAbs — CH103 (4), VRC01 (7), CH31–
CH34 (8), and b12 (5, 6) — as well as non-neutralizing CD4bs b6
mAb and CD4-Fc to 31 YU2 gp120 core single-point mutants (Figure 2). Single-point mutations outside the CD4bs did not affect
CH98 binding. Within the CD4bs, mutations in position 365 and
368 abrogated binding of all CD4bs BnAbs tested, but not mAb
b6, and mutations in positions 282, 461, and 473 reduced CH98
binding to 55%, 64%, and 31%, respectively (Figure 2). Overall,
CH98 was the BnAb least sensitive to the mutations represented
in the panel, which indicates that these positions are less relevant
for CH98 binding to its cognate epitope than for the other CD4bs
BnAbs. The only antibodies sensitive to all the mutations that also
affected CH98 binding were the BnAbs CH103 and VRC01.
Comparison of CH98 with CD4bs mAbs CH103 and VRC01. CH103
and VRC01 bind to the CD4bs with 2 distinct modes of epitope
recognition: CH103 uses a loop dominated mode of interaction
including all VHDJH and VLJL CDRs (4), whereas VRC01 contacts
the CD4bs by mimicking CD4 with a large footprint that is dominated by HCDR2 and encompasses both heavy and light chains
(40). To determine whether CH98 falls into one of these categories, we threaded the CH98 heavy and light chains onto the gp120complexed structure coordinates of CH103 (4) and VRC01 (40).
CH98 threading on the VRC01 gp120-complexed structure
resulted in steric clashes between the LCDR3 of CH98 and the D
loop of gp120 (Figure 3A). Relaxation of the model to alleviate the

Figure 2

Effect of point mutation of the YU2 core protein on CD4-Fc and on
CH98, CH31–CH34, VRC01 and b12 CD4bs BnAbs, and the non-neutralizing CD4bs b6 mAb. The effect of point mutations on the binding to
the YU2 core protein of CH98 and other CD4bs mAbs and CD4-Fc is
expressed as percentage normalized to binding to the WT YU2 gp120
core protein and color coded as indicated. Positioning within the CD4bs
(green), or adjacent or nearby (black), is indicated at far right.
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was comparable to that previously observed for the CD4bs BnAb
CH103 (Supplemental Figure 7).
In the same assay, CH5329 plasma from the same specimen
from which CH98 BnAb was isolated was found to be positive for
SSA and dsDNA antibodies
(mean ± SD, 268 ± 29 and 163 ± 22
response units [RU], respectively;
Figure 4B).
In HEp-2 cell IFA staining,
CH98 displayed diffuse fine
granular cytoplasmic staining, exhibited stronger binding
to dividing cells, and bound to
intracellular vesicles in a subset of
Figure 3
HEp-2 cells (Figure 4, C–E). CH98
Threading of CH98 onto the gp120 complexed structures of CD4bs VRC01 and CH103 BnAbs. (A) CH98
reactivity with 9,400 additional
model based on threading onto the gp120 complexed VRC01 crystal structure. The CH98 heavy chain (HC;
dark blue) and light chain (LC; light blue) threaded onto the VRC01 structure complexed with gp120 (gray) human proteins was screened
resulted in an incompatible model, with a clash between the gp120 D loop (red) and the LCDR3 (green). using microarray technology (28).
(B) CH98 model based on threading onto the gp120 complexed CH103 crystal structure. The CH98 heavy CH98 showed polyreactivity with
chain (dark blue) and light chain (light blue) threaded onto the CH103 structure complexed with gp120 (gray) numerous human antigens, as
resulted in a model in which HCDR3 (magenta) dominates the binding to the CD4bs region and engages measured by 1 log stronger bindin direct contact with gp120 residues in positions 365, 368, 473, and 282, all of which affect CH98 binding. ing to more than 90% of the test
The residue in position 461 makes direct contact with LCDR1. Each residue that affects CH98 binding in the
proteins than the non-polyreacepitope mapping is illustrated using the corresponding color in Figure 2.
tive control antibodies 151K and
palivizumab. CH98 also bound
with higher affinity, measured
clashes resulted in a complex with a binding energy score of –31.96 as a >2 log increase in binding compared with antibody controls,
Rosetta energy units (REU; see Methods), which was higher (i.e., to STUB1 (also known as CHIP), an E3 ubiquitin-protein ligase
less favorable) than those of both the solved VRC01-gp120 complex (Figure 4, F and G). Binding of CH98 and CH5329 plasma to
and the CH98 complex modeled in the CH103 mode of recognition STUB1 were confirmed in direct-binding ELISA with an endpoint
(–40.84, and –37.86 REU, respectively). Conversely, CH98 threading titer of 3.3 μg/ml for CH98 and plasma titer of 270 (Supplemental
onto the gp120-complexed CH103 crystal structure resulted in a Figure 8, A and B). We previously demonstrated that members of
model compatible with a CH103-like mode of antigen recognition the CD4bs BnAb CH103 clonal lineage displayed reactivity with
(Figure 3B). Between the 2 mAbs, aa sequence homology was 36% dsDNA and with UBE3A, another E3 ubiquitin-protein ligase (4).
and 56% for the VHDJH and VLJL, respectively (Supplemental Figure 5 Such reactivity was also shared by the CD4bs BnAb VRC01 (4).
and Supplemental Table 3). This model supported the observed However, these BnAbs did not bind to STUB1, and CH98 did not
binding data (Figure 2) and predicted that all the heavy and light bind to UBE3A (data not shown).
Taken together, these findings suggested that the immune
chain CDRs of CH98 make direct contact with the 5 residues affectsystem dysregulation that allows for production of autoreactive
ing CH98 binding to the YU2 gp120 core (Supplemental Table 4).
In particular, D461 was predicted to contact LCDR1 (Supple- antibodies during SLE may have played a permissive role in the
mental Figure 6A), which is 9 aa long and underwent a 5-aa dele- development and maturation of the BnAb CH98. Moreover, the
tion. Therefore, we asked whether a LCDR1 deletion-reverted similarities between CH98 and the SLE autoantibodies of long
CH98 would be compatible with the gp120-complexed CH103 HCDR3 and dsDNA reactivity are suggestive of similar pools of B
mode of recognition. Adoption of the canonical conformation for cells and mechanisms of their origin.
a LCDR1 of length 14, as defined by North and colleagues (41),
allowed the deletion-reverted LCDR1 to avoid steric clashes at the Discussion
gp120 interface; however, the binding energy score of the complex Here, we describe an individual who, when studied 14 years after
was less favorable than that of the mature CH98 complex (–35.09 HIV-1 transmission and 6 years after onset of SLE, controlled
versus –37.86 REU; Supplemental Figure 6B). Our interpretation her viral load off antiretroviral therapy (ART) and developed
is that the 15-nt deletion in the CH98 LCDR1 may have played a plasma BnAb activity.
An open question regarding the development of BnAbs in HIV-1–
favorable role during the process of affinity maturation of CH98.
CH98 BnAb reactivity with human proteins. In a panel of 9 autoanti- positive subjects is whether acquisition of autoreactivity is a comgens associated with presence of autoimmune diseases (Sjogren’s mon prerequisite for the development of neutralization breadth.
syndrome antigens A and B [SSA and SSB, respectively], Smith We have previously described the CH103 CD4bs BnAb isolated
antigen [Sm], ribonucleoprotein [RNP], centromere B [Cent B], from an SLE-negative, chronically HIV-1–infected individual and
histone, scleroderma 70 [Scl 70] and Jo-1 proteins, and dsDNA), demonstrated that antibodies in the CH103 clonal lineage acquired
CH98 reacted with dsDNA (Figure 4A). CH98 binding to dsDNA autoreactivity with a number of autoantigens, including dsDNA,
1838
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Figure 4

Autoreactivity of CH98. (A) CH98
reactivity against common antigens associated with autoimmune
diseases, tested with a commercial ANA-II Plus test system. The
threshold for positivity was 120 RU
(dashed line). (B) CH5329 plasma
reactivity against common antigens associated with autoimmune
diseases, tested with the commercial ANA-II Plus test system.
Results from 3 independent experiments are shown. The threshold for negativity was 100 RU
(solid line), and that for positivity was 120 RU (dashed line);
values of 100–120 RU were
considered equivocal specimens. (C–E) Hep-C IFA staining of BnAb CH98. Antibody
concentration was 25 μg/ml,
and exposure time was 8 seconds.
Original magnification, ×40; inset
in D is enlarged ×1.5. (F and G)
Reactivity of CH98 on a panel of
9,400 human proteins tested using
a ProtoArray 5 microchip, compared with nonautoreactive mAb
151K (F) or palivizumab (G). Values for STUB1 are encircled.

concurrently with acquisition of HIV-1 neutralization breadth (4).
We have also described an individual in whom the onset of gp41
MPER 2F5-like BnAb plasma activity was temporally associated
with the development of plasma dsDNA and Jo-1 autoantigen reactivity, without appearance of any clinical manifestation of autoimmune disease (42). Thus, in some individuals, acquisition of BnAb
activity is clearly associated with the acquisition of autoreactivity.
Antibodies to dsDNA are a hallmark of SLE and are present in
approximately 70% of subjects with SLE, but only 0.5% of SLEnegative individuals (32). Conversely, dsDNA antibodies are not a
typical finding during HIV-1 infection, but have been commonly
reported in the plasma of the few SLE subjects with HIV-1 infection (30, 33). The presence of plasma dsDNA antibodies has been
documented in subjects diagnosed with SLE both after and before
HIV-1 diagnosis (91.7% and 64.3%, respectively) (30). The incidence
of plasma BnAbs in these reported cases, however, is unknown.
We report herein a monoclonal HIV-1 BnAb, CH98, isolated
from a chronically HIV-1–infected individual who subsequently
developed SLE. CH98 neutralized HIV-1 through binding to the
CD4bs on HIV-1 gp120 and reacted with dsDNA at levels comparable to those previously observed for the CD4bs BnAb CH103.
CH98 accounted for only a portion of the plasma neutralization

breadth (65.9%). This observation, in conjunction with the finding that RSC3 plasma absorption only partially abrogated plasma neutralization (30%–55%), implies that other neutralizing
antibody specificities contributed to the overall plasma neutralization breadth in this individual. These data are in line with previous observations indicating that plasma neutralization breadth
can be mediated by a polyclonal response comprising antibodies
with distinct specificities and variable degrees of breadth (43–45).
Using a combination of epitope mapping and threading of the
CH98 heavy and light chains onto the gp120-complexed structure coordinates of CD4bs BnAbs, we determined that CH98
likely uses a CH103-like Env loop mode of epitope recognition
that involves all the heavy and light chain CDRs. Conversely,
CH98 threading onto the gp120-complexed structure of VRC01
resulted in steric clashes between the LCDR3 of CH98 and the
D loop of gp120. This result was not unexpected: VRC01 and
all VRC01-like antibodies had unusually short LCDR3s (5 residues), and it has been suggested that the VRC01-like orientation of gp120 binding does not leave enough space between the
antibody and the gp120 D loop to accommodate longer LCDR3s
(46). Indeed, CH98 has a 12-residue-long LCDR3, and therefore
our model is compatible with this hypothesis.
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CH98 was also characterized by a short LCDR1 (9 aa) that
underwent a 5-aa deletion during the process of affinity maturation. This 15-nt deletion in CH98 LCDR1 was preceded by an AID
hotspot. AID hotspots regulate secondary antibody diversification and are directly involved in the process of somatic hypermutation (47, 48). Since we predicted a less favorable binding energy
score of the deletion-reverted CH98 complex compared with the
mature CH98 complex, our interpretation is that, similar to our
prior observation for CH103 (4), a single macromutation may have
improved binding to the cognate epitope. In addition, LCDR1s
shorter than 11 aa are rare (46), but commonly found among
CD4bs BnAbs (4, 46), and both CH103 and VRC01 also have deletions in their LCDR1s (4, 40). We interpret the disproportionate
frequency of short LCDR1s among CD4bs BnAbs as being indicative of a common selection process of CD4bs BnAbs that favors
antibodies with shortened LCDR1s.
This is the first chronically infected SLE individual with concomitant HIV-1 infection that we have been able to study, and it
was striking that this individual also had robust plasma BnAb
activity, given that the incidence of chronically HIV-1–infected
subjects with this level of plasma neutralization breadth is only
approximately 20% (49–52).
In a literature review from 1981 to 2012 by Carugati and colleagues, of 53 HIV-1/SLE patients, 54.7% were diagnosed with
HIV-1 before SLE (33). The diagnosis of HIV-1 in our subject
preceded that of SLE, and we cannot conclude that the CH98
maturation was initiated as part of the SLE-induced autoreactive
response, nor can we exclude the possibility that silent SLE was
present before the time of HIV-1 diagnosis.
When generated, BnAbs appear late (2–4 years) after HIV-1 transmission, and serum neutralization breadth correlates with viral
load levels (49). This has been interpreted as an indication that persistent antigen stimulation is required to develop neutralization
breadth (53–55). In stark contrast, our study subject developed
BnAbs while controlling viremia, which suggests that acquisition
of HIV-1 neutralization breadth may not always require chronic
stimulation with high levels of HIV-1 viremia. A possible explanation is that the maturation of CH98 was not hindered in this subject by immune tolerance control mechanisms, thus facilitating
the acquisition of mutations required to achieve neutralization
breadth, possibly driven by exposure to both HIV-1 and autoantigens (21, 24, 27). The low viral load and normal CD4 count of this
subject while off ART could not be explained by HIV-1–controlling
HLA types (56) or by HIV-1 infection with a nef-defective strain
(57, 58); studies are in progress to determine whether the presence
of SLE contributed to virus control.
Kobie and colleagues recently identified an autoreactive plasma
antibody population (9G4 anti-idiotype antibodies) that is commonly found in SLE subjects and is responsible for serum HIV-1
neutralization breadth in ART-naive, SLE-negative, chronically
HIV-1–infected subjects; the authors proposed that this kind of
antibody may derive from the same pool of B cells of SLE-induced
antibodies (34). The BnAb CH98 differs from 9G4-positive antibodies in that it uses a VH3–30 gene segment, not VH4–34, which defines
9G4 antibodies. Therefore, our findings demonstrated that autoreactive antibody populations beyond 9G4-positive antibodies have
the potential to broadly neutralize HIV-1 strains in SLE subjects.
In conclusion, we demonstrated that a virus-controller SLE
patient with chronic HIV-1 infection developed the highly mutated CD4bs BnAb CH98, and this antibody displayed characteris1840

tics typical of SLE-induced autoantibodies. Our findings support
the hypothesis that lax mechanisms of tolerance control associated with SLE may have favored the maturation of this BnAb by
favoring its evasion from deletion during the process of somatic
maturation and the acquisition of reactivity with self-antigens.
Moreover, our data support the concept that BnAbs develop from
a similar pool of B cells as do autoimmune B cells in SLE.
Methods

Patient information. Subject CH5329 is a female patient, aged 33 years at the
initiation of the study. At 19 years of age, the patient was diagnosed with
HIV-1; at 27 years of age (8 years after HIV-1 diagnosis), the subject was diagnosed with SLE. The patient sought health care at the Duke University Medical Center Clinics in 2009 (age 31 years). At admission, her general health
conditions were overall good with no fever, chills, night sweats, nausea, vomiting, or diarrhea. CD4 count was 460 cells/mm3. She had not received any
ART. SLE diagnosis was confirmed at admission based on American College
of Rheumatology criteria for SLE (59): malar rash, discoid rash, photosensitivity, arthritis, and presence of plasma speckled anti-nuclear antibody titer
of 160. The subject also reported a history of seizures that preceded the diagnosis of both SLE and HIV-1 infection, as well as a history of asthma, which
was controlled by daily triamcinolone and albuterol. In 2009, her plasma was
negative for SSA, SSB, RNP, Sm, and dsDNA antibody. Serum complement
levels were normal. Her SLE was treated with plaquenil from 2005 to January
2008 and 7.5 mg methotrexate once weekly from 2006 to December 2012,
when plaquenil was restarted and continued up to date.
The patient was enrolled in 2011 in the CHAVI008A study of chronic
HIV-1–infected individuals. Plasma, PBMCs, and leukapheresis samples
were collected and studied. At enrollment, the subject had received no
ART, and her CD4 count and viral load were 568 cells/mm3 and 4,150 HIV
RNA copies/ml, respectively. Her MHC class I phenotype was HLA-B7 and
HLA-B40. Analysis of 64 HIV-1 3′-half genome sequences generated by
the single genome amplification method showed the intact nef gene in all
sequences (Supplemental Figure 9). In 2011, her plasma was positive for
dsDNA antibodies; negative for SSA, SSB, Sm, RNP, Scl 70, Jo-1, Cent B,
and histone antibodies; and showed an ANA-positive pattern in HEp-2 cell
intracellular fluorescence staining with an endpoint titer of 320.
Cell cultures. IgG+ memory cells were isolated from PBMCs as previously
described (11). Briefly, IgG+ memory B cells were isolated from frozen
PBMCs by 2 rounds of separation using magnetic beads (11). First, PBMCs
were incubated for 30 minutes at 4°C with PE-conjugated anti-CD2 (catalog no. 555327), anti-CD14 (catalog no. 555398), anti-CD16 (catalog no.
555407), anti-CD235a (catalog no. 555570), and anti-IgD (catalog no.
555779) antibodies (all from BD Biosciences — Pharmingen), followed
by a 15-minute incubation with anti-PE microbeads (Miltenyi Biotec) at
4°C. After washing, cells were passed through magnetic columns using
the Deplete_S program of the AutoMACs separator (Miltenyi Biotec).
The negative fraction was then incubated for 15 minutes with anti-IgG
microbeads (catalog no. 130-047-501; Miltenyi Biotec). After washing, IgG+
memory B cells were selected using the Possel_S program of the AutoMACs
separator (11). All steps of the separation procedure were performed using
cold PBS with 0.1% BSA buffer (PBSB). IgG+ memory B cells were stimulated for 14 days in vitro to induce proliferation and differentiation into
antibody-secreting cells for functional studies on the culture supernatants,
using a previously described stimulation protocol (11). Briefly, cells were
resuspended in complete medium containing 2.5 μg/ml CpG ODN2006
(tlrl-2006; InvivoGen), 5 μM CHK2 kinase inhibitor (Calbiochem/EMD
Chemicals), and EBV (200 μl supernatant of B95-8 cells/104 memory B
cells) and incubated in bulk overnight at 37°C in 5% CO2 (11). After overnight incubation, 28,800 viable IgG+ memory B cells were manually trans-
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ferred at an average density of 3 cells/well in 96-well round-bottomed tissue culture plates containing ODN2006, CHK2 kinase inhibitor, and 5,000
irradiated (7,500 cGy) CD40 ligand–expressing L cells per well. The cell
density of 3 cells per well was chosen to achieve the expansion of a single
cell in the majority of wells, according to Poisson distribution and previous experimental observations using this method. Medium was refreshed
after 7 days, and supernatants were harvested at day 14 (11). Cell culture
supernatants were screened for IgG levels, differential binding to RSC3
and RSC3Δ371I, and neutralization of the clade A.Q23.17 HIV-1 strain.
This screening strategy was selected to isolate BnAbs based on the observed
plasma differential binding to RSC3 and RSC3Δ371I and the high plasma
ID50 A.Q23.17 HIV-1 strain neutralization. The RSC3 gp120 core antigen
is a protein designed to retain the antigenic structure of the neutralizing
surface of the CD4bs while eliminating other antigenic regions of the
HIV-1 envelope glycoprotein, and the deletion of a single aa in position 371
(RSC3Δ371I; originally described as ΔRSC3) abrogates or heavily reduces
the binding of CD4bs BnAbs (7). Since CD4bs BnAbs such as VRC01,
VRC01-like, and CH103 have been previously isolated from memory B
cells that bound to RSC3 using antigen-specific cell sorting (4, 7, 44, 60),
we decided to use this protein to screen cultured memory B cells cultured
to retrieve CD4bs BnAbs using our culture system.
Isolation of V(D)J Ig regions and expression of recombinant antibody. RNA from
positive cultures was extracted using standard procedures (RNeasy minikit; Qiagen), and the genes encoding Ig VHDJH and VLJL rearrangements
were amplified by RT and nested PCR without cloning, using a previously
reported method (11, 36). Briefly, reverse transcription was performed at
55°C for 1 hour after the addition of 50 U/reaction of Superscript III RT
(Life Technologies) and 0.5 μM human IgG, IgM, IgD, IgA1, IgA2, Igκ, and
Igλ constant-region primers. Separate reactions were used to amplify individual families of VH, Vκ, and Vλ genes from the cDNA template; this was
performed using 2 rounds of PCR: first round, 5 μl RT reaction product,
5 U HotStar Taq Plus (Qiagen), 0.2 mM deoxynucleoside triphosphates
(dNTPs), 0.5 μM nested constant-region primers (IgH consisting of IgM,
IgD, IgG, IgA1 and IgA2; Igκ or Igλ), and matched variable-region primers; second round, 2.5 μl first-round reaction product, 5 U HotStar Taq
Plus, 0.2 mM dNTPs, 0.5 μM nested constant-region and nested variableregion primers. First-round PCR was cycled as follows: 95°C for 5 minutes;
35 cycles at 95°C for 30 seconds, 55°C (VH and Vκ) or 50°C (Vλ) for 60 seconds,
and 72°C for 90 seconds; and 1 cycle at 72°C for 7 minutes. Second-round
PCR was similar, except that the extension step was performed at 58°C
(VH), 60°C (Vκ), or 64°C (Vλ). Samples of VH, Vκ, and Vλ chain PCR products were analyzed on 2% agarose gels (Qiagen). Products were sequenced
in the forward and reverse directions using a BigDye sequencing kit on
an ABI 3700 instrument (Applied Biosystems). Sequence base calling was
performed by using Phred. V, D, and J region genes and mutations were
analyzed using the SoDA information system (61). All primers used for the
second round of PCR included tag sequences at the 5′ end of each primer
to permit the assembly of the VH and VL genes into functional linear Ig
gene expression cassettes by overlapping PCR, as reported elsewhere (36).
Expression of recombinant antibody. Isolated Ig VHDJH/VLJL gene pairs were
assembled by PCR into linear full-length Ig heavy- and light-chain gene
expression cassettes as previously described (36). The human embryonic
kidney cell line 293T (ATCC) was grown to near confluence in 6-well tissue
culture plates (BD) and transfected with 2 μg/well purified PCR-produced
IgH and IgL linear Ig gene expression cassettes using Effectene (Qiagen).
Supernatants were harvested from the transfected 293T cells after 3 days
of incubation at 37°C in 5% CO2.
Neutralization assays. Neutralizing antibody assays with TZM-bl cells were
performed as previously described (62). Purified recombinant antibodies
were tested starting at a 50-μg/ml final concentration and titrated using

serial 3-fold dilutions. Plasma antibody was tested starting at a 1:20 dilution. Pseudotyped lentiviruses were added to the antibody dilutions at a
predetermined titer to produce measurable infection and incubated for
1 hour. TZM-bl cells were added and incubated for 48 hours before lysis,
after which the supernatant was measured for firefly luciferase (Britelite
Plus; Perkin-Elmer) activity using a luminometer. Data were calculated as
the reduction in luminescence compared with control wells and reported
as IC50 (in μg/ml) for purified recombinant antibodies or ID 50 titer (as
1/dilution) for plasma (62). Plasma neutralization resistance was defined
as an ID50 titer <20. For further information on the viruses used for neutralization screening, see Supplemental Table 5.
Direct binding ELISAs. Direct binding assays were performed in 384-well
plates as previously described (11). Briefly, plates were coated overnight at
4°C with 15 μl purified proteins at optimized concentrations and blocked
with assay diluent (PBS containing 4% [w/v] whey protein, 15% normal goat
serum, 0.5% Tween 20, and 0.05% sodium azide) for 2 hours at room temperature. Primary culture supernatants were screened at a 1:3 dilution in assay
diluent, whereas purified recombinant antibodies were tested using 3-fold
serial dilutions starting at 100 μg/ml. 10 μl of primary antibodies were
added to each well and incubated for 2 hours at room temperature. Plates
were developed using 15 μl/well horseradish peroxidase–conjugated goat
anti-human IgG Fc (catalog no. 109-035-098; Jackson ImmunoResearch
Laboratories) at a 1:9,000 dilution in 5% goat serum and PBS for 1 hour,
followed by 30 μl/well of SureBlue Reserve TMB One Component microwell
peroxidase substrate (catalog no. 53-00-03; KPL). Development was
stopped with 15 μl/well of 0.1 M HCl, and plates were read at OD450 with a
VersaMax microplate reader (Molecular Devices).
HEp-2 cell staining. Indirect immunofluorescence binding of mAbs or plasma to HEp-2 cells (Zeuss Scientific) was performed as previously described
(24). Briefly, 20 μl of antibody at 50 μg/ml or plasma in serial dilutions was
aliquoted onto a predetermined spot on the surface of a slide (ANA HEp-2
kit). After incubation for 25 minutes at room temperature and washes,
20 μl of secondary antibody (goat anti-human Ig FITC at 20 μg/ml; Southern Biotech) was added to each spot and incubated in a humid chamber for
25 minutes in the dark. After washing and drying, a drop of 33% glycerol
was added to each spot, and the slide was covered with a 24- by 60-mm
coverslip. Images were taken on an Olympus AX70 instrument with a SpotFlex FX1520 CCD and with a UPlanFL 40× 0.75-NA objective at 25°C in
the FITC channel using SPOT software. All images were acquired for 8 or
10 seconds. Image layout and scaling were performed with Adobe Photoshop without image manipulation.
Antibody reactivity against human host cellular antigens. Binding of CH98 to
human host cellular antigens was performed using a ProtoArray 5 microchip (Life Technologies) according to the manufacturer’s instructions. In
brief, ProtoArray 5 microchips were blocked and exposed to 2 μg/ml CH98
or a human myeloma protein (151 K; Southern Biotech), or palivizumab for
90 minutes at 4°C. Protein-antibody interactions were detected by 1 μg/ml
Alexa Fluor 647–conjugated anti-human IgG. The arrays were scanned at
635 nm with 10-μm resolution, using 100% power and 600 gain (GenePix
4000B scanner; Molecular Devices). Fluorescence intensities were quantified
using GenePix Pro 5.0 (Molecular Devices). Lot-specific protein spot definitions were provided by the microchip manufacturer and aligned to the image.
Epitope mapping. A panel of 32 HIV-1 YU2 gp120 core mutants displayed
on S. cerevisiae (38) was probed for binding to CD4bs mAbs and CD4-Fc
(Sino Biological). For each core mutant, 600,000 induced yeast cells were
incubated with anti-HA Ab clone 16B12 (Covance) to detect expression
and CD4bs mAbs or CD4-Fc in 50 μl PBSB in black 96-well plates (Greiner
Bio One) for 1 hour at room temperature while shaking. Yeast cells were
washed twice with 200 μl cold PBSB and subsequently incubated with
goat anti-mouse and anti-human detection antibodies conjugated to
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Alexa Fluor 488 or Alexa Fluor 647 (Life Technologies) in 50 μl PBSB for
20 minutes shaking at room temperature and covered from light. Yeast
cells were washed once as above, suspended in 200 μl PBSB, and analyzed
for fluorescence using a MACSQuant (Miltenyi Biotec) flow cytometer. For
each mutant, 10,000 events were gated on HA signal, and median fluorescence intensities (MFIs) were determined and normalized for expression. This method has been previously used to test approximately 2 dozen
mAbs (binding within and outside the CD4bs), and the observed results
were consistent both with crystal structures whenever they were available and with epitope maps generated by other means, whether or not the
cocrystals/other maps were generated with YU2 (38, 39). Additionally, fine
specificity differences in the residues identified as involved in binding for
multiple antibodies have been found to correlate with either broad or narrow neutralization activity (S.K. Grimm and M.E. Ackerman, unpublished
observations), further supporting the validity of the method.
CH98 homology modeling. Homology models of CH98 in complex with
gp120 were built using Rosetta protein modeling software (63). The
sequence of the heavy and light chains of CH98 were threaded independently onto the template’s (CH103, ref. 4; VRC01, ref. 40) heavy and light
chain structures (PDB codes 4JAN and 3NGB, respectively). The bestscoring heavy and light chain models from the independent threading
runs were then superposed onto the paired heavy and light chain template, and this model was allowed to relax using the Rosetta FastRelax
protocol. After relaxation, the model was minimized with AMBER (64).
This homology model of the unliganded antibody was then superposed
into the solved antibody-gp120 complex structure. The Rosetta loop
refinement protocol (65) was used to allow for loop flexibility in the V5
loop of gp120 (a superposition of solved gp120 structures from the PDB
indicated the V5 loop to be the most flexible loop in the CD4 binding
site) and the HCDR3 loop (the most flexible of the 6 CDR loops; ref. 66).
The top-scoring complex model after loop refinement then underwent
a last round of relaxation with Rosetta to further refine the complex. A
model of the LCDR1 deletion-reverted CH98 complex was built using
the above homology modeling procedure using the CH98 mature light
chain sequence with the 5-aa GSYNL insertion in LCDR1. One additional
step was added to the procedure that placed the LCDR1 in its canonical
conformation based on length and sequence using the CDR structural
definitions of North and colleagues (41). Predicted binding energy scores
for all modeled complexes were computed in Rosetta by subtracting the
energy score of the antibody and gp120 alone from the energy score of the
antibody-gp120 complex and expressed as REU.
Preparation of libraries for 454 DNA pyrosequencing. V, D, and J segments
of the Ig heavy chain were amplified and sequenced using the 454 pyrosequencing platform as previously described (8). Briefly, a cDNA library
was constructed by isolation of mRNA from 22 × 106 PBMCs using
the Oligotex kit (Qiagen) and concentrated to 26 μl in elution buffer.
Reverse transcription was performed in 2 35-μl reactions (13 μl mRNA,
3 μl oligo(dT)12–18 at 0.5 μg/μl [Invitrogen], 7 μl 5× first-strand buffer
[Invitrogen], 3 μl RNase Out [Invitrogen], 3 μl 0.1M DTT, 3 μl dNTP mix,
1. Bonsignori M, et al. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine
design. Trends Microbiol. 2012;20(11):532–539.
2. Buchacher A, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for
peripheral blood lymphocyte immortalization.
AIDS Res Hum Retroviruses. 1994;10(4):359–369.
3. Calarese DA, et al. Dissection of the carbohydrate
specificity of the broadly neutralizing anti-HIV-1
antibody 2G12. Proc Natl Acad Sci U S A. 2005;
102(38):13372–13377.
4. Liao HX, et al. Co-evolution of a broadly neutraliz1842

each at 10 mM, and 3 μl SuperScript II [Invitrogen]) and incubated at
42°C for 2 hours. The cDNA was combined, purified, and eluted in 20 μl
elution buffer (NucleoSpin Extract II kit; Clontech). Heavy and light chain
variable region rearrangements were amplified by PCR from 5 μl cDNA
as template (the rough equivalent of transcripts from 5.5 × 106 PBMCs)
using the Phusion High Fidelity enzyme (New England Biolabs) according
to the manufacturer’s instructions. The 50 μl reaction mix was composed
of water, 10 μl 5× buffer, 1 μl dNTP mix, each at 10 mM, 1 μl of each primer at 25 μM, and 1 μl enzyme. Gene-specific forward primers for VH3 gene
amplification were VH3 Leader A, C, D, E, and F, and the reverse primers
were 3′Cγ-CH1 and 3′Cμ-CH1 (8, 67). The forward primer for VL2 amplification was 5′L-VL1/2-5′-GCACAGGGTCCTGGGCCCAGTCTG-3′, and
the reverse primer was 3′CL-5′-CACCAGTGTGGCCTTGTTGGCTTG-3′.
The PCR cycling program was run according to Phusion enzyme instructions, using 55°C as the annealing temperature for the heavy chain reaction and 66°C for the lambda. The PCR products at the expected size
(450–500 bp) were gel purified (Qiagen), followed by phenol/chloroform
extraction. 454 pyrosequencing of the PCR products was performed on
a GS FLX sequencing instrument (Roche-454; Life Sciences) using the
manufacturer’s suggested methods and reagents.
Statistics. Values were expressed as mean ± SEM of 2 independent experiments where indicated. Statistical analysis was performed using GraphPad
Prism 5 (GraphPad Software).
Study approval. This study was approved by the Duke IRB and the NIH
NIAID DAIDS PSRC committee. Informed consent was received from the
participant prior to inclusion in the study according to U.S. federal, local,
and Duke University Medical Center regulations.
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